Telix Pharmaceuticals
FDA Approves Telix Radiopharmaceutical Imaging Agent Gozellix to ID PSMA-Positive Prostate Cancer
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
In Brief This Week: Iovance, Telix, 23andMe, Anixa Biosciences, Foresight, Lucence
News items for the week of Feb. 24, 2025.
Telix Seeking FDA Approval for Kidney Cancer Radiopharmaceutical Imaging Agent
The firm's biologics license application for TLX250-CDx was granted priority review and a decision is expected in August.
Telix Pharmaceuticals Acquires Early-Stage Assets From ImaginAb, Shares Late-Stage Pipeline Updates
Premium
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both diagnostically and therapeutically.
FDA Allowing Compassionate Use Access to Telix's Glioma PET Imaging Agent
Telix will seek FDA approval to sell TLX101-CDx as an imaging agent for advanced glioma patients.